Search

Displaying results 5241 - 5250 of 7498 in total
  1. Drug

    Azadirachta indica leaf

    go.drugbank.com/drugs/DB14352
    Approved

    It is not an approved drug.

  2. Drug

    Butriptyline

    go.drugbank.com/drugs/DB09016
    ApprovedWithdrawn

    Butriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline.

    Categories: Non-Selective Monoamine Reuptake Inhibitors, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Lofentanil

    go.drugbank.com/drugs/DB09174
    ExperimentalIllicit

    It displays most similarity to carfentanil (4-carbomethoxyfentanyl) and is considered to be slightly more potent than this drug.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition

  5. Drug

    Dilmapimod

    go.drugbank.com/drugs/DB12140
    Investigational

    Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}

  6. Drug

    ISIS 14803

    go.drugbank.com/drugs/DB05803
    Investigational

    ISIS 14803 is a 20-unit antisense phosphorothioate oligodeoxynucleotide that binds to hepatitis C virus (HCV) RNA at the translation initiation region of the internal ribosome entry site (IRES) and inhibits

  7. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market. … NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression.

  8. Drug

    Honey

    go.drugbank.com/drugs/DB14242
    ApprovedInvestigational

    It is not an approved drug.

  9. Drug

    GT 389-255

    go.drugbank.com/drugs/DB05894
    Experimental

    It is expected to block fat absorption with fewer side effects than currently marketed lipase inhibitors.

  10. Drug

    Clesacostat

    go.drugbank.com/drugs/DB18956
    Investigational

    Clesacostat is under investigation in clinical trial NCT04321031 (Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)).